Human variability in polymorphic CYP2D6 metabolism: is the kinetic default uncertainty factor adequate?-Reference-Cited by-同舟云学术

Human variability in polymorphic CYP2D6 metabolism: is the kinetic default uncertainty factor adequate?

Published:2002-11 Issue:11 Volume:40 Page:1633-1656
ISSN:0278-6915
Container-title:Food and Chemical Toxicology
language:en
Short-container-title:Food and Chemical Toxicology

Author:

Dorne J.L.C.M,Walton K,Slob W,Renwick A.G

Publisher

Elsevier BV

Subject

Toxicology,General Medicine,Food Science

Reference152 articles.

1. Imipramine and desipramine disposition in the elderly;Abernethy;Journal of Pharmacology and Experimental Therapeutics,1985

2. Role of polymorphic debrisoquin 4-hydroxylase activity in the stereoselective disposition of mexiletine in humans;Abolfathi;Journal of Pharmacology and Experimental Therapeutics,1993

3. Hydroxylation polymorphism of debrisoquine and mephenytoin in European populations;Alvan;European Journal of Clinical Pharmacology,1990

4. The Lognormal Distribution;Aitchison,1966

5. Estimating steady state desipramine levels in noninstitutionalized elderly patients using single dose disposition parameters;Antal;Journal of Clinical Psychopharmacology,1982

Cited by 62 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and Tolerability of Antimicrobial Agents in the Older Patient;Drugs & Aging;2023-03-28

2. Distributions for time, interspecies and intraspecies extrapolation for deriving occupational exposure limits;Journal of Applied Toxicology;2022-03-13

3. Human variability in polymorphic CYP2D6 metabolism: Implications for the risk assessment of chemicals in food and emerging designer drugs;Environment International;2021-11

4. Inter-phenotypic differences in CYP2C9 and CYP2C19 metabolism: Bayesian meta-regression of human population variability in kinetics and application in chemical risk assessment;Toxicology Letters;2021-02

5. Biological evaluation of medical devices—Part 16: Toxicokinetic study design for degradation products and leachables;ANSI/AAMI/ISO 10993-16:2017; Biological evaluation of medical devices—Part 16: Toxicokinetic study design for degradation products and leachables;2020-10-30